Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving AML care beyond one-size-fits-all induction and transplant algorithms.

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...

In Tank Chats #167, we examine the French Panhard EBR, an innovative postwar armored car designed for speed, reconnaissance, and firepower. With its unique eight-wheeled, two-axle steering system and ...

AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that suppress their growth ...

The Panhard Dyna Z, produced from 1954 to 1959, was an advanced vehicle for its time. Although most Americans are unfamiliar with the former French brand, Panhard started out as Panhard & Levassor ...

Few cars are harder to spot on British roads than the Panhard PL 17, of which only eight remain at the time of writing. Back in the day, Panhard made uniquely French vehicles that did not really ...

The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based ...

The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...

A bone marrow or stem cell transplant may be beneficial for people with intermediate- to high-risk acute myeloid leukemia (AML) who are in remission and can tolerate an intensive treatment plan. Acute ...

New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...